Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.72 |
| ▸ | FNTA | P49354 | 12/20 | 0.65 |
| ▸ | FNTB | P49356 | 12/20 | 0.65 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296459 | 1.00 | CYP3A4 (0.72) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL4300749 | 1.00 | CYP3A4 (0.72) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL11947161 | 0.93 | CYP3A4 (0.61) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL13573620 | 0.92 | CYP3A4 (0.69) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL11954233 | 0.91 | CYP3A4 (0.59) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL11947147 | 0.90 | FNTA (0.81) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL23633189 | 0.90 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL21544535 | 0.90 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL22772860 | 0.90 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL8097 | 0.90 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107963-B1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2006-03-22 | — | — | EP | claimed |
| US-20020151563-A1 | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth | PFIZER INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002078706-A1 | FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG COA REDUCTASE INHIBITORS FOR THE INHIBITION FOR THE TREATMENT OF CANCER | PFIZER PRODUCTS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | claimed |
| EP-1107963-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000012499-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| EP-2545919-A1 | Treatment of synucleinopathies | Link Medicine Corporation (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120196766-A1 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof | FOURIE ANNE MADELEINE (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196766-A1 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof | FOURIE ANNE MADELEINE (US) | 2012-08-02 | — | — | US | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-20020151563-A1 | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002078706-A1 | FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG COA REDUCTASE INHIBITORS FOR THE INHIBITION FOR THE TREATMENT OF CANCER | PFIZER PRODUCTS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6294552-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS, SUCH AS CANCER, IN MAMMALS. THE INVENTION ALSO RELATES TO METHODS OF INHIBITING ABNORMAL CELL GROWTH, INCLUDING CANCER, IN A MAMMAL BY ADMINISTERING THE COMPOUNDS OF FORMULA 1 TO A MAMMAL REQUIRING | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1107963-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000012499-A1 | ALKYNYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | CCNA1, NRAS, CCNT1 | CYP3A4 1460/4885FNTA 1890/4885FNTB 2727/4885 |
| US-20020151563-A1 | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth | HMGCR, FNTA, FDPS | CYP3A4 2579/4885FNTA 2/4885FNTB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.